In trials, Revolution Medicines' daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.

Daraxonrasib is taken daily by mouth. Instead of binding to KRAS directly, it attaches to a molecule called cyclophilin A in cells that helps fold proteins into their final 3D structures. This protein ...

The Food and Drug Administration (FDA) cleared the once-daily tablet, Rasonque, for certain adults with metastatic pancreatic ...

The agency’s officials announced it gave the pill daraxonrasib approval more than six months ahead of a target date.

The federal rules about the drug-fighting drug seemed to carry a message that some patients can be trusted; others, not so ...

A Richmond County judge has vacated the murder conviction and life sentence of a mother found guilty in the 2014 death of her ...

Dolly Parton’s death is bringing new attention to her history of recurring kidney stones. A Duke Health urologist explains ...

Two Frankfurt airport workers have died after contracting malaria from a mosquito believed to have hitched a ride on an ...

The Owosso Fire Department has purchased a new ambulance that will help first responders continue to provide high-quality ...

The Department of Health and Human Services has launched an effort to streamline clinical research, and legislation is ...

Illinois agreed to a federal court order issued late last week that will temporarily shield some medical professionals and ...